3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
34
Lung Neoplasms
11
Neoplasms
4
Adenocarcinoma of Lung
4
Brain Neoplasms
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Neoplasm Metastasis
2
NSCLC
2
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Diseases
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
1
Carcinoma
1
Breast Neoplasms
1
Advanced Non-small Cell Lung Cancer
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
149
Docetaxel
139
Paclitaxel
127
Trastuzumab
120
Tamoxifen
110
Capecitabine
104
Letrozole
92
Epirubicin
79
Doxorubicin
70
Anastrozole
70
exemestane
67
Fulvestrant
65
Fluorouracil
61
Radiotherapy
60
pertuzumab
40
Gemcitabine
39
Carboplatin
38
Vinorelbine
34
Goserelin
34
Bevacizumab
29
Zoledronic Acid
28
Methotrexate
28
Chemotherapy, Adjuvant
28
eribulin
27
Lapatinib
25
ribociclib
24
palbociclib
24
Drug Therapy
22
130-nm albumin-bound paclitaxel
20
pegfilgrastim
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Breast Neoplasms
×
Gefitinib
×
Clear all
NCT00357734
2016-08-30
Iressa Follow-up Trial
AstraZeneca
Phase 3
Completed
14 enrolled
10 charts